ADVANCED VIRAL RESEARCH CORP
NT 10-Q, 1996-05-14
PHARMACEUTICAL PREPARATIONS
Previous: LIPOSOME CO INC, 10-Q, 1996-05-14
Next: HALSEY DRUG CO INC/NEW, S-1, 1996-05-14



                U.S. Securities and Exchange Commission
                        Washington, D.C.  20549        
                                                  SEC FILE NUMBER
                                                  33-2262-A
                                                  CUSIP NUMBER
                                                  007928 10 4
                              FORM 12b-25
     
                      NOTIFICATION OF LATE FILING
     
       (Check One): Form 10-K           Form 20-F      Form 11-K 
                    Form 10-Q and Form 10-QSB  X       Form N-SAR
     
                    For Period Ended: March 31, 1996
                    [  ] Transition Report on Form 10-K
                    [  ] Transition Report on Form 20-F
                    [  ] Transition Report on Form 11-K
                    [  ] Transition Report on Form 10-Q
                    [  ] Transition Report on Form N-SAR
                    For Transition Period Ended:
       
     Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
     
     If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
       
PART I - REGISTRANT INFORMATION
       
     Full Name of Registrant:
     Advanced Viral Research Corp.

     Former Name if Applicable:
     N/A

     Address of Principal Executive Office (Street and Number):
     1250 East Hallandale Beach Blvd., Suite 510, 
     Hallandale, FL 33009

PART II-RULES 12b-25(b) AND (c)

       If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed (Check box if appropriate)

X  (a)  The reason described in reasonable detail in Part III of this form 
could not be eliminated without unreasonable effort or expense;

X  (b)  The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on
or before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following the prescribed due
date; and

   (c)  The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
     
PART III - NARRATIVE

     State below in reasonable detail the reason why the Form 10-K and form
10-KSB, 20-F, 11-K, 10-Q and 10-QSB, N-SAR, or the transition report or
portion thereof could not be filed within the prescribed time period:
     
Computer difficulties


PART IV- OTHER INFORMATION

     (1)     Name and telephone number of person to contact in regard to this
notification:
       
William Bregman  (954) 458-7636
       
     (2)     Have all other periodic reports required under section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? 
     
If answer is no identify reports.  Yes
     
     (3)     Is it anticipated that any significant change in result of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?  No
     
     If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
     
     ADVANCED VIRAL RESEARCH CORP.
     (Name of Registrant as Specified in Charter)
       
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
       
       
       Date: May 14, 1996               By:  William Bregman
                                             Chief Executive Officer
     


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission